Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centro De Immunología Molecular holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 1 pending office action. The prosecution is streamlined, with 1 distinct examiner and 1 distinct art unit managing the active workload. This concentration indicates that the portfolio's current focus is on a specific technical area that falls under the jurisdiction of 1 specialized group at the USPTO.
The busiest examiner for this portfolio is KIM, YUNSOO, who is currently handling 1 pending office action. Since KIM, YUNSOO is the only examiner assigned to the portfolio's pending matters, the immediate success of the prosecution depends entirely on this individual's review. The 1 distinct art unit involved requires a targeted response that addresses the specific concerns of the examiner. Practitioners should analyze the examiner's past decisions in Biotechnology & Pharmaceuticals to better anticipate the next steps in the prosecution process and ensure the 1 pending office action is resolved efficiently.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786094 | STABLE HIGH-CONCENTRATION FORMULATION OF NIMOTUZUMAB ANTIBODY | KIM, YUNSOO | 48d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17786094 | STABLE HIGH-CONCENTRATION FORMULATION OF NIMOTUZUMAB ANTIBODY | KIM, YUNSOO | 1641 | §102 | Final Rejection | 48d | Pending | Jun 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial